Phathom Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (PHAT)

CUSIP: 71722W107

Q2 2024 13F Holders as of 30 Jun 2024

Holder snapshot 7 signals
Share change
+2,735,886
Put/Call ratio
7.5%
SEC-reported price per share
$10.30
Number of holders
113
Value change
+$27,856,700
Number of buys
64
Open additional details 1 more signal available
Number of sells
36
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
80,377,000

Security key

71722W107

Report period

Q2 2024

Institutions

113

Top holders

10

Ownership snapshot

Top reported holders of PHAT - Phathom Pharmaceuticals, Inc. - Common Stock, par value $0.0001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Frazier Life Sciences Man...
Disclosed value leader
Frazier Life Sciences Man...
Comparable rows
15/15
Latest evidence
31 Mar 2024
13F 3/4/5 Lead comparable stake: 13% Showing 1-6 of 15 holder rows.

Quick read

Frazier Life Sciences Management, L.P. leads the comparable SEC ownership view at 13%.

15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Frazier Life Sciences Management, L.P.'s linked filing trail.
Comparable ownership Top 5
Frazier Life Sciences Management,... 13%
Medicxi Ventures Management (Jers... 9.3%
Carlyle Group Inc. 4.4%
Invesco Ltd. 3.9%
TAKEDA PHARMACEUTICAL CO LTD 3.9%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Frazier Life Sciences Management, L.P.
13F
Company
13F
13%
$107,360,543
10,109,279 shares
31 Mar 2024
Medicxi Ventures Management (Jersey) Ltd
13F 3/4/5
Company · 10%+ Owner
9.3%
$79,273,755
7,464,572 shares
31 Mar 2024
Carlyle Group Inc.
13F
Company
13F
4.4%
$37,101,133
3,496,808 shares
31 Mar 2024
Invesco Ltd.
13F
Company
13F
3.9%
$33,556,959
3,159,789 shares
31 Mar 2024
TAKEDA PHARMACEUTICAL CO LTD
13F 3/4/5
Company · 10%+ Owner
3.9%
$33,487,165
3,153,217 shares
31 Mar 2024
BlackRock Finance, Inc.
13F
Company
13F
3.4%
$29,155,935
2,745,380 shares
31 Mar 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
113
Shares
58,109,780
Rows available
113
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q2 2024 vs Q1 2024 Across Filers

Q1 2024 holders
112
Q2 2024 holders
113
Holder diff
1
Investor Q1 2024 Shares Q2 2024 Shares Share Diff Share Chg % Q1 2024 value Q2 2024 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .